U.K. Drug Experts Wanted GSK's Avandia Withdrawn In July, But EU Processes Intervened
EU regulators will discuss the fate of GlaxoSmithKline's Avandia at an extraordinary meeting on Sept. 8, but a decision is not expected until the end of the month.
More from Archive
More from Pink Sheet
Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.
Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.
Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.